TABLE 3.

Tentative CLSI M45 4th Edition breakpoints for Pseudomonas species other than P. aeruginosa

Antimicrobial agent	MIC breakpointsa			Disk diffusion breakpoints
	S	I	R	S	I	R
Piperacillin-tazobactam	≤16/4	32/4	≥64/4	≥22	17–21	≤16
Ceftazidime	≤8	16	≥32	≥19	15–18	≤14
Cefepime	≤8	16	≥32	≥19	14–18	≤13
Imipenem	≤2	4	≥8	≥20	15–19	≤14
Meropenem	≤2	4	≥8	≥18	14–17	≤13
Tobramycin	≤1	2	≥4	≥21	15–20	≤14
Ciprofloxacin	≤0.5	1	≥2	≥25	19–24	≤18
Levofloxacin	≤1	2	≥4	≥22	15–21	≤14
Amikacin	≤4	8	≥16	≥23	19–22	≤18

^a Interpretive criteria are adapted from those for Pseudomonas aeruginosa, as published in CLSI M100 in conjunction with evaluation of MIC distributions from surveillance data/clinical laboratories and PK/PD properties of the individual agent, with the exception of amikacin. For amikacin, Enterobacterales systemic breakpoints were considered and deemed appropriate based on the amikacin MIC distribution of non-aeruginosa Pseudomonas.